Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Mendus

3.50 SEK+2.04 %20/11 17:29
Less than 1K followers

IMMU

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+2.04 %
-31.64 %
-47.76 %
-39.24 %
-37.50 %
-33.96 %
-69.98 %
-96.26 %
-97.36 %

Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.

Read more
Market cap
226.75M SEK
Turnover
83.74K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
I’ve created a dedicated thread for Mendus, but my English is poor and I don’t know the industry at all, so there are bound to be mistranslations and misunderstandings. I looked up information on Inderes’ site, especially from the extensive report. Naturally, I googled for info and...
7/23/2024, 7:30 PM
by Sijoittaja-alokas
11
Tässä on Antin tuoreet kommentit Mendusin tuoreesta ilixadenceli-tutkimuksen yhteistyöstä. Mendus announced on Tuesday that the company will start a new ilixadencel trial in collaboration with the French cancer center Institut Bergonié. The trial will combine ilixadencel with the...
7/24/2024, 4:39 AM
by Sijoittaja-alokas
3
An interesting discovery, but so are many other Swedish biopharma/biotech firms. You can put money into these like a lottery ticket and maybe one eventually succeeds, while the rest engage in endless dilution of their share capital and wash away investors’ money. The discussion surrounding...
7/23/2024, 8:38 PM
by Acumen
3
MFN – 5 May 25 Mendus AB (publ): Mendus strengthens late-stage clinical developmen... Mendus AB ('Mendus' publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced the appointment of Tariq Mughal, MD FRCP FRCPath, as Chief...
5/5/2025, 12:38 PM
by Clark kent
2
Tässä on Antin yhtiöraportti Menduksen Q2:n jälkeen. For Mendus, Q2’24 marked the start of the pivotal CADENCE trial in acute myeloid leukemia (AML). The company also announced plans to restart clinical development of ilixadencel in soft tissue sarcomas (STS). In parallel, Mendus...
8/26/2024, 6:40 PM
by Sijoittaja-alokas
2
Mendus published its second-quarter report on Friday, August 23. In an interview with Antti, CEO Erik Manting summarizes what happened during the second quarter, highlights the key achievements of the CADENCE trial, and discusses the new study for the drug Ilixadencel. Inderes Mendus...
8/24/2024, 12:03 PM
by Sijoittaja-alokas
2
Creeping upwards without any news. I couldn’t find an explanation right away. Of course, there have been similar spikes before. Does anyone have any information or an educated guess? The company management loaded up on shares a while back.
7/6/2026, 11:12 AM
by Tannenberg
1
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
11/2
2027

Annual report '26

11/5
2027

General meeting '27

Press release2026-11-18 13:26

Redeye: Mendus: Phase III Win for AML Vaccine Supports Vididencel

Mendus
Third party research2026-11-11 13:36

Mendus: Immune signals across AML and CML; Q326 results - Edison

Mendus’s Q326 results reflect continued execution of its expanded vididencel strategy across acute myeloid leukaemia (AML) and chronic myeloid leukaemia (CML), supported by initial immunological data from both indications. In the Phase IIb CADENCE trial...

Mendus
Regulatory press release2026-11-11 08:00

Mendus AB Interim Report July – September 2026

Mendus

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release2026-11-11 08:00

Mendus AB Delårsrapport juli - september 2026

Mendus
Press release2026-11-11 08:00

Mendus announces initial immunological data from CADENCE and VITAL-CML indicating vididencel improves immune competence across indications

Mendus
Press release2026-11-11 08:00

Mendus meddelar preliminära immunologiska data från CADENCE och VITAL-CML som visar att vididencel stärker immunförsvarets funktion vid flera indikationer

Mendus
Press release2026-11-10 08:00

Mendus and NorthX Biologics expand collaboration to include production of memory NK cell therapies

Mendus
Press release2026-11-10 08:00

Mendus och NorthX Biologics utökar sitt samarbete till att omfatta produktion av minnes-NK-cell terapier

Mendus
Regulatory press release2026-11-06 08:00

Mendus Announces Nomination Committee for the 2027 Annual General Meeting

Mendus
Regulatory press release2026-11-06 08:00

Mendus tillkännager valberedning inför årsstämman 2027

Mendus
Press release2026-11-04 08:00

Invitation to presentation of Mendus' third quarter 2026 financial report and business update

Mendus
Press release2026-11-04 08:00

Inbjudan till presentation av Mendus delårsrapport för tredje kvartalet 2026 och verksamhetsuppdatering

Mendus
Press release2026-10-05 08:00

Mendus announces appointment of Hans Preusting as Chief Operating Officer

Mendus
Press release2026-10-05 08:00

Mendus utser Hans Preusting till Chief Operating Officer

Mendus
Press release2026-10-01 08:00

Mendus announces presentation of updated ADVANCE II data and VITAL-CML progress

Mendus
Press release2026-10-01 08:00

Mendus rapporterar presentation av uppdaterade ADVANCE II-data och VITAL-CML framsteg

Mendus
Third party research2026-09-17 08:18

Mendus: DIVA starts; testing combination with Ven+Aza - Edison

Mendus has initiated the Phase Ib DIVA trial, marking the first clinical evaluation of vididencel in combination with venetoclax and azacitidine (Ven+Aza) in newly diagnosed acute myeloid leukaemia (AML) patients considered unfit for intensive induction...

Mendus
Third party research2026-09-16 14:41

Mendus: DIVA opens a new AML front - Edison

Mendus has initiated the Phase Ib DIVA trial, evaluating vididencel in combination with venetoclax and azacitidine (Ven+Aza) in newly diagnosed acute myeloid leukaemia (AML) patients with measurable residual disease (MRD) who are considered unfit for...

Mendus
Press release2026-09-16 08:00

Mendus announces initiation of the DIVA trial

Mendus
Press release2026-09-16 08:00

Mendus meddelar starten av DIVA-studien

Mendus